Breast CancerPhase 1NCT05239143
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study testing P-MUC1C-ALLO1 CAR-T cells and Rimiducid in people with Breast Cancer and Ovarian Cancer, run by Poseida Therapeutics, Inc. at 14 sites in United States.
Trial summary
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer
- What is being tested?
- P-MUC1C-ALLO1 CAR-T cells and Rimiducid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 14 sitesUnited States
- Study dates
- 15 Feb 2022to Apr 2039
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males or females, Subjects ≥18 years with life expectancy >3 months
- Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
- Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
- Must have adequate vital organ function within pre-determined parameters
- Must have archived tumor tissue available or consent to a biopsy collection
Show all 9Show fewer
- Must be willing to practice birth control
- Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
- Must have recovered from toxicities due to prior therapies
Who cannot join
- Has inadequate venous access
- Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Is pregnant or lactating
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
- Has an active systemic (viral, bacterial, or fungal) infection
Show all 15Show fewer
- Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
- Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
- Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion
- Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
- Has known CNS metastases or symptomatic CNS involvement
- Has a history of significant liver disease or active liver disease
- Has a history of known genetic predisposition to HLH/MAS
- Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy
Trial locations and contacts
14 sites in 1 country.
14 sites in 1 country
United States14 sites
University of Maryland Cancer Center
Baltimore, Maryland, 21201
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218
MD Anderson Cancer Center
Houston, Texas, 77030
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
University of California, Irvine Medical Center
Irvine, California, 92868
Cedars Sinai Medical Center
Los Angeles, California, 90048
University of Nebraska Medical Center
Omaha, Nebraska, 68198
NEXT Oncology
San Antonio, Texas, 78229
University of California, San Diego
San Diego, California, 92037
University of California, San Francisco
San Francisco, California, 94143
Montefiore Medical Center
The Bronx, New York, 10467
University of Kansas Cancer Center
Westwood, Kansas, 66205
Cancer Center of Kansas
Wichita, Kansas, 67214
About this study
Official title: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Read the detailed description
This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.
Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma
- Being tested
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Medical subject headings
- Breast Neoplasms, Ovarian Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms, Carcinoma, Renal Cell, Nasopharyngeal Neoplasms, Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
P-MUC1C-ALLO1 CAR-T cellsBiological
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
RimiducidDrug
Rimiducid (safety switch activator) may be administered as indicated.
| Study group | Role | What they receive |
|---|---|---|
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A) | Experimental | * Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B) | Experimental | * Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C) | Experimental | * Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D) | Experimental | * Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1) | Experimental | * Single ascending A1 dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E) | Experimental | * Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F) | Experimental | * Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M) | Experimental | * Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen.
* Rimiducid may be administered as indicated. Receives: Biological: P-MUC1C-ALLO1 CAR-T cells; Drug: Rimiducid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Number of subjects with a dose limiting toxicity (DLT)
Measured: Baseline through Day 28
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Frequency and severity of adverse events
Measured: Baseline through 15 years
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR)
Measured: Baseline through 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2022
- Study start15 Feb 2022
- Primary completionApr 2039 (estimated)
- Study completionApr 2039 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at recommended phase 2 dose (RP2D)
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poseida Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Simon Heidegger, M.D., Study director, Lead Medical Director, Oncology, Genentech Research Early Development
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05239143
- Sponsor's protocol ID
- P-MUC1C-ALLO1-001
- Status last verified
- Nov 2026
- First submitted
- 3 Feb 2022
- Last updated
- 5 Nov 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Gorodetska I, Samusieva A, Lahuta T, Ponomarova O, Socha O, Kozeretska I. Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.
PubMed 40443562
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
- ClinicalTrials.gov ID
- NCT05239143
- Acronym / sponsor ID
- P-MUC1C-ALLO1-001
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Poseida Therapeutics, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Feb 2022 (actual)
- Primary completion
- Apr 2039 (estimated)
- Study completion
- Apr 2039 (estimated)
- First posted
- 14 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Detailed description
This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.
Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 8
- Model description
- Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at recommended phase 2 dose (RP2D)
| Arm | Type | Receives |
|---|---|---|
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 2. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Single ascending A1 dose cohorts, given in a single intravenous infusion of CAR-T cells, following lymphodepletion regimen 1. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Cyclic administration of ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen. * Rimiducid may be administered as indicated. |
| P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M) | Experimental | Biological: P-MUC1C-ALLO1 CAR-T cells, Drug: Rimiducid* Single ascending dose cohorts, given in a single intravenous infusion of CAR-T cells, following assigned lymphodepletion regimen. * Rimiducid may be administered as indicated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Males or females, Subjects ≥18 years with life expectancy >3 months
- Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
- Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
- Must have adequate vital organ function within pre-determined parameters
Key exclusion criteria (15 listed)
- Has inadequate venous access
- Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Is pregnant or lactating
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| P-MUC1C-ALLO1 CAR-T cellsP-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. | Biological | P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M) |
| RimiducidRimiducid (safety switch activator) may be administered as indicated. | Drug | P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D), P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E), P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M) |
Primary outcome
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Time frame: Baseline through Day 28
Number of subjects with a dose limiting toxicity (DLT)
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Time frame: Baseline through 15 years
Frequency and severity of adverse events
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Time frame: Baseline through 15 years
According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Derived from this study: PubMed 40443562Gorodetska I, Samusieva A, Lahuta T, Ponomarova O, Socha O, Kozeretska I. Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Simon Heidegger, M.D. study director
Lead Medical Director, Oncology, Genentech Research Early Development
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing P-MUC1C-ALLO1 CAR-T cells and Rimiducid in people with Breast Cancer and Ovarian Cancer, run by Poseida Therapeutics, Inc. at 14 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1 (time frame: Baseline through Day 28). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05239143, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.